Psyence Group Inc. (EKW0)
XFRA 
OTC PINK Primary XFRA Summary
EKW0 Chart
Why Is Psyence Biomedical (PBM) Stock Up 163% Today?
Psyence Biomedical (NASDAQ: PBM ) stock is rocketing higher on Thursday after providing investors with export and clinical trial updates. Starting with its exports, Psyence Biomedical notes that it is shipping nature-derived psilocybin to Australia.
Psyence Group Inc. (EKW0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Psyence Group Inc. ever had a stock split?
Psyence Group Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jody Aufrichtig CEO | XFRA Exchange | CA74449Q2053 ISIN |
| CA Country | - Employees | - Last Dividend | 21 Dec 2010 Last Split | - IPO Date |
Overview
Psyence Group Inc. is a pioneering life science biotechnology entity focused on the cultivation and production of psilocybin mushrooms, rooted in Toronto, Canada. Founded in 2019, the company stands at the forefront of harnessing natural psilocybin for the potential treatment of various mental health disorders and other medical conditions. Psyence Group Inc. dedicates its efforts to developing pharmaceutical-grade psilocybin preparations intended to address psychological trauma and a spectrum of diagnosable disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), along with grief and bereavement. By delving into the therapeutic prospects of psilocybin, Psyence Group aims to chart new territories in mental health treatment and recovery.
Products and Services
- Pharmaceutical Psilocybin Preparations
- Natural Psilocybin Cultivation
- GOODMIND Nutraceutical Products
Psyence Group Inc. is at the forefront of producing pharmaceutical-grade psilocybin doses. These preparations are meticulously developed for the treatment of mental health disorders including anxiety, depression, PTSD, as well as for assisting individuals in coping with grief and bereavement. The company's initiative to produce standardized, reliable doses of psilocybin underscores its commitment to contributing to the field of psychopharmacology and mental health alleviation.
At the heart of Psyence Group's operation is its involvement in the commercial cultivation of psilocybin mushrooms. This endeavor enables the company to maintain a consistent supply of natural psilocybin, the active compound researched for its efficacy in treating a wide range of mental health issues. Through controlled cultivation practices, Psyence ensures the production of high-quality psilocybin for its research and pharmaceutical developments.
Expanding its market reach, Psyence Group has ventured into the development, distribution, and sale of non-psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. This product line represents the company's diversification into over-the-counter wellness products, offering consumers functional mushroom-based supplements aimed at enhancing mental and physical well-being without the inclusion of psychotropic substances.
